Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hyperfine ( (HYPR) ) has issued an update.
On January 12, 2026, Hyperfine reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, highlighting a record fourth-quarter revenue of about $5.3 million, up 127% year-on-year and 54% sequentially, driven by placements across hospital, neurology office and international markets. For full-year 2025, revenue is expected to reach approximately $13.5 million, a modest 5% increase over 2024, while preliminary net cash burn excluding financings improved, declining 30% year-on-year in the fourth quarter to about $5.7 million and 22% for the full year to about $29.9 million, leaving the company with an estimated $35.1 million in cash and cash equivalents at year-end; these trends suggest strengthening commercial traction for its next-generation Swoop® system and Optive AI™ software alongside tighter cash management, though figures remain subject to final audit and a full earnings release expected in March 2026.
The most recent analyst rating on (HYPR) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.
Spark’s Take on HYPR Stock
According to Spark, TipRanks’ AI Analyst, HYPR is a Neutral.
Hyperfine’s overall stock score reflects strong revenue growth and a solid cash position, which are offset by significant profitability challenges and negative valuation metrics. The positive earnings call sentiment and market expansion plans provide some optimism, but the financial performance and valuation concerns weigh heavily on the score.
To see Spark’s full report on HYPR stock, click here.
More about Hyperfine
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology company focused on brain imaging, best known for the Swoop® system, the first FDA-cleared, portable, ultra‑low‑field MRI system for brain imaging at multiple points of care. Its AI‑powered, portable MR Imaging® devices target hospitals, neurology offices and other settings where conventional, fixed MRI systems are impractical, aiming to make diagnostic brain imaging more accessible and clinically useful worldwide.
Average Trading Volume: 798,508
Technical Sentiment Signal: Sell
Current Market Cap: $96.33M
For a thorough assessment of HYPR stock, go to TipRanks’ Stock Analysis page.